Zeke Capital Advisors’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Zeke Capital Advisors’s Portfolio KRBP Stock Details KRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$19.3K	Hold	3,567	–	–	﹤0.01%	469
2022 Q3	$31K	Hold	3,567	–	–	﹤0.01%	464
2022 Q2	$45K	Hold	3,567	–	–	﹤0.01%	476
2022 Q1	$91K	Buy	3,567 +1,670	+88%	+$49.4K	﹤0.01%	505
2021 Q4	$87K	Hold	1,897	–	–	0.01%	308
2021 Q3	$175K	Buy	1,897 +1,334	+237%	+$138K	0.01%	283
2021 Q2	$81K	Sell	563 -1,004	-64%	-$252K	0.01%	325
2021 Q1	$442K	Sell	1,567 -46	-3%	-$13.5K	0.03%	148
2020 Q4	$410K	Buy	+1,613	New	+$458K	0.03%	147

Other funds holding KRBP

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Zeke Capital Advisors's KRBP Position: Q4 2022 in Review

Zeke Capital Advisors held its Kiromic BioPharma, Inc. Common Stock (KRBP) position steady in Q4 2022 at 3,567 shares worth $19.3K. The position accounts for ﹤0.01% of the portfolio, ranked #469.

Zeke Capital Advisors first reported a position in KRBP in Q4 2020 and has held it in 9 quarters since. The position peaked at $442K in Q1 2021. 12 funds tracked by Wall St. Rank hold KRBP as of Q4 2022.

Zeke Capital Advisors held 3,567 shares of Kiromic BioPharma, Inc. Common Stock worth $19.3K as of Q4 2022.
Zeke Capital Advisors left its Kiromic BioPharma, Inc. Common Stock share count unchanged in Q4 2022.
Kiromic BioPharma, Inc. Common Stock made up ﹤0.01% of Zeke Capital Advisors's portfolio in Q4 2022, its #469 holding.
Zeke Capital Advisors first reported a position in Kiromic BioPharma, Inc. Common Stock in Q4 2020 and has held it in 9 quarters since.
Zeke Capital Advisors's Kiromic BioPharma, Inc. Common Stock position peaked at $442K in Q1 2021.
12 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.